drugset / Trial / NCT06151210

Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

NCT06151210

Phase 3 Completed 467 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis

Timeline

Start
2024-01-31
Primary completion
2025-07-10
Completion
2025-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject DA-5219 Unknown
Comparator Stillen Tab. Unknown

Indications